Indian Army Medicines Tender 2026 Procurement of Lignocaine HCl Jelly to Dopamine Injections - 2026

Tender Overview

The procurement opportunity is issued by the Indian Army under the Department of Military Affairs for a diversified list of pharmaceutical products, including topical anesthetics, injections, tablets, suspensions, and syrups. Estimated value is ₹74,277.62 with a 19-item BOQ spanning drugs like Lignocaine HCl Jelly 2% tubes, Paracetamol combinations, Pantoprazole injections, and Dopamine HCl injections, among others. The scope emphasizes medical consumables and formulations suitable for field and institutional use, with a flexible quantity clause allowing up to ±25% variation. The location is not specified in the tender data. This notice highlights the breadth of medicines and the need for consistent supply within contract rates. Key differentiators include a broad product mix and standard delivery terms tied to military medical supply needs.

Technical Specifications & Requirements

• No explicit technical specifications are provided in the tender data. The BOQ lists 19 items with broad medicine categories including: topical anesthetics, antiemetics, analgesics, anti-ulcer, anti-allergics, antihypertensives, anti-diabetics, anti-infectives, and anti-fungals.
• Given the absence of standard numbers, bidders should prepare for generic pharmaceutical compliance, with emphasis on regulatory eligibility and reliable national drug distribution capabilities.
• The lack of explicit IS/ISO references means bidders may propose standard GMP-compliant manufacturing practices and WHO-GMP aligned supply capabilities, along with proper packaging norms for sterile vials, injections, and syrups.
• Delivery readiness and cold chain feasibility may be essential for injectables and suspensions, along with batch-wise traceability documentation.
• EMD and exact quantities are not disclosed; bidders should monitor for reserve quantities and confirm with issuing authority.

Terms, Conditions & Eligibility

• Option clause allows ±25% quantity variation at contract award and during the currency of the contract, with delivery periods recalculated accordingly.
• Delivery timeline references the last date of the original delivery order; additional time is calculated if extension occurs, with a minimum 30 days.
• No explicit EMD amount or payment terms are stated in the data; bidders must rely on standard government tender practices and verify during bid submission.
• The procurement must comply with generic government tender terms and reserve rights for quantity adjustments and extensions as specified.
• 19-item BoQ requires diverse supplier capabilities across multiple pharmaceutical categories; bidders should demonstrate robust supply chain and regulatory compliance.